Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05892185
Other study ID # MC-001-081
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 31, 2023
Est. completion date July 19, 2024

Study information

Verified date May 2023
Source Mingche Biotechnology CO., LTD
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of glaucoma device in the treatment of primary open-angle glaucoma.


Description:

A prospective, randomized, single-blind, positive control design was used to study primary open-angle glaucoma. Eligible subjects were screened and randomly assigned to the experimental group and the control group.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date July 19, 2024
Est. primary completion date January 12, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria - Patients with a clinical diagnosis of primary open-angle glaucoma (POAG) who could undergo minimally invasive glaucoma surgery (MIGS) as judged by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
GELA
GELA glaucoma implant
XEN
XEN gel stent implant

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mingche Biotechnology CO., LTD

Outcome

Type Measure Description Time frame Safety issue
Primary Success rate at 6 months after surgery Success rate defined as the percentage of total cases in which IOP decreased =20% and/or IOP =21mmHg while using the same or lower amount of IOP-lowering medications compared to baseline at 6 month after surgery. 6 months
Secondary IOP reduction The IOP of the subjects before and 6 months after surgery was calculated in both experiment group and control group. 6 months
Secondary topical IOP-lowering medications Counting by class of drug of topical IOP lowering medications before and 6-month after surgery. 6 months
Secondary Success rate 12 months after operation Success rate defined as the percentage of total cases in which IOP decreased =20% and/or IOP =21mmHg while using the same or lower amount of IOP-lowering medications compared to baseline at 12 month after surgery. 12 months
Secondary Adverse event Adverse events was recorded and summarized. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A